Currently, there are 8.59M common shares owned by the public and among those 8.10M shares have been available to trade.
The company’s stock has a 5-day price change of -3.87% and -54.98% over the past three months. CTXR shares are trading -62.75% year to date (YTD), with the 12-month market performance down to -92.77% lower. It has a 12-month low price of $1.21 and touched a high of $26.75 over the same period. CTXR has an average intraday trading volume of 151.69K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.73%, -29.99%, and -83.80% respectively.
Institutional ownership of Citius Pharmaceuticals Inc (NASDAQ: CTXR) shares accounts for 8.33% of the company’s 8.59M shares outstanding.
It has a market capitalization of $12.80M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$5.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 27.18% over the week and 13.34% over the month.
Analysts forecast that Citius Pharmaceuticals Inc (CTXR) will achieve an EPS of 1.3 for the current quarter, -0.52 for the next quarter and 2.98 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 1.3 while analysts give the company a high EPS estimate of 1.3. Comparatively, EPS for the current quarter was -1.25 a year ago. Earnings per share for the fiscal year are expected to increase by 122.61%, and 249.63% over the next financial year.
Looking at the support for the CTXR, a number of firms have released research notes about the stock. D. Boral Capital stated their Buy rating for the stock in a research note on December 30, 2024, with the firm’s price target at $9. Maxim Group coverage for the Citius Pharmaceuticals Inc (CTXR) stock in a research note released on November 30, 2021 offered a Buy rating with a price target of $4.
